Kinnate Biopharma (NASDAQ:KNTE – Get Rating) issued its earnings results on Wednesday. The company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.02), Yahoo Finance reports.
Kinnate Biopharma Stock Down 2.6 %
KNTE stock traded down $0.14 during midday trading on Friday, reaching $5.32. 50,883 shares of the company’s stock traded hands, compared to its average volume of 114,619. The company has a 50-day simple moving average of $6.19 and a two-hundred day simple moving average of $8.24. Kinnate Biopharma has a 1-year low of $3.30 and a 1-year high of $15.86. The company has a market cap of $234.98 million, a price-to-earnings ratio of -2.16 and a beta of 0.20.
Institutional Investors Weigh In On Kinnate Biopharma
A number of hedge funds and other institutional investors have recently bought and sold shares of KNTE. Barclays PLC boosted its position in Kinnate Biopharma by 58.1% in the 4th quarter. Barclays PLC now owns 24,386 shares of the company’s stock valued at $149,000 after buying an additional 8,962 shares during the last quarter. Jane Street Group LLC bought a new position in Kinnate Biopharma in the 2nd quarter valued at $147,000. SVB Financial Group bought a new position in Kinnate Biopharma in the 4th quarter valued at $143,000. Marshall Wace LLP bought a new position in Kinnate Biopharma in the 3rd quarter valued at $137,000. Finally, Cubist Systematic Strategies LLC bought a new position in Kinnate Biopharma in the 3rd quarter valued at $123,000. 98.68% of the stock is owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
Kinnate Biopharma Company Profile
Kinnate Biopharma Inc, a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program.
- Get a free copy of the StockNews.com research report on Kinnate Biopharma (KNTE)
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
- Europe Raises Interest Rates, Should the Fed Follow?
- PacWest Bancorp May Escape a Credit Downgrade After this Happens
- Dollar General Offers Great Prices, but the Stock isn’t a Value
Receive News & Ratings for Kinnate Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kinnate Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.